Evidence Level
Metformin (Longevity Context)
Metformin's potential to enhance longevity is supported by robust observational data but remains unproven definitively in interventional studies involving non-diabetic individuals. A landmark 2014 study by Bannister et al. demonstrated that patients with type 2 diabetes treated with metformin had a 15% lower mortality rate compared to matched non-diabetic controls, suggesting a possible longevity benefit (Bannister et al., 2014). The TAME trial, led by Nir Barzilai and approved by the FDA, represents a significant step in testing metformin's anti-aging effects. This trial will evaluate composite age-related outcomes in approximately 3,000 participants aged 65-79 (Barzilai et al., 2021).
Gandini et al. conducted a systematic review and meta-analysis of 47 studies involving 65,540 cancer cases, finding that metformin use in diabetic patients was associated with a 31% reduction in cancer incidence and a 34% lower cancer mortality rate (Gandini et al., 2014). This highlights metformin's potential beyond diabetes management.
However, a key controversy arises from Konopka et al.'s 2019 study, which showed that metformin blunted exercise-induced mitochondrial improvements in older adults. The study found that metformin reduced gains in insulin sensitivity and VO2 max after 12 weeks of aerobic exercise training, potentially by inhibiting mitochondrial adaptations (Konopka et al., 2019). This raises questions about the interplay between metformin's AMPK activation and exercise-induced benefits.
Metformin is a prescription medication and should only be used under medical supervision.